ClinicalTrials.gg
Active, not recruitingNCT06688058Updated Nov 12, 2026

A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)

A Phase 1 interventional study of V540D and GARDASIL®9 in Healthy, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 4 sites in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

Updated Nov 12, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Researchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV. Most people's immune system can fight HPV infection and it goes away without treatment. For some people, HPV infections can last longer and may cause cancer years later.

A standard vaccine to prevent HPV-related cancers is GARDASIL®9 (G9). G9 protects against 9 types of HPV but it does not protect against other types of HPV. The study vaccine (called V540D) is designed to protect against the same HPV types that G9 protects against plus other HPV types. The main goal of this study is to learn about the safety of V540D in healthy adults and if people tolerate it.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

  • Is in good health based on medical history, physical examination, vital sign (VS) measurements and (ECGs) performed before randomization

Exclusion criteria

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

  • Has a history of abnormal Pap smears, HPV- related external genital lesions (eg, condyloma acuminate, vulval intraepithelial neoplasia (VIN), or prostatic intraepithelial neoplasia (PIN)) or external genital cancer (eg, penile cancer), HPV-related vaginal or anal lesions (eg, condyloma acuminata or vaginal intraepithelial neoplasia (VaIN)) or vaginal or anal cancer
  • Has a history of cancer ()
  • Has received any HPV vaccine or is expected to receive any HPV vaccine during the study, outside the protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    V540D

    Participants will receive vaccinations with V540D.

    Biological: V540D

  • Active comparator
    GARDASIL®9

    Participants will receive vaccinations with GARDASIL®9.

    Biological: GARDASIL®9

Interventions

  • BiologicalV540D

    Experimental vaccine and adjuvant administered via intramuscular (IM) injection

  • BiologicalGARDASIL®9

    Suspension administered via IM injection

    Also known as: G9, V503

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience a Solicited Injection-Site Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 6 months

  2. Number of Participants Who Experience a Solicited Systemic AE

    Solicited systemic AEs include headache, fatigue, nausea, dizziness, muscle aches, joint pain.

    Time frame: Up to approximately 6 months

  3. Number of Participants Who Experience Immediate Reactions Occurring Within 30 Minutes After Any Vaccination

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 6 months

  4. Number of Participants Who Experience Unsolicited AEs

    An unsolicited AE is an event that is not predefined as a solicited AE or is predefined as a solicited AE but reported at any time outside the solicited time period.

    Time frame: Up to approximately 7 months

  5. Number of Participants Who Experience a Serious Adverse Event (SAE)

    SAEs include AEs that result in any of the following outcomes: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect.

    Time frame: Up to approximately 18 months

  6. Number of Participants Who Experience a Medically-Attended AE (MAAE)

    AEs in which medical attention is received during an unscheduled, non-routine outpatient visit, such as an emergency department visit, office visit, or an urgent care visit with any medical personnel for any reason. Routine visits are not considered MAAEs. Examples of routine visits include physical examination, wellness visits, or vaccinations.

    Time frame: Up to approximately 18 months

  7. Number of Participants Who Experience an Event of Clinical Interest (ECI)

    ECIs are defined as an overdose of Sponsor's product, drug-induced liver injury events, or potential immune-mediated diseases (pIMDs).

    Time frame: Up to approximately 18 months

Secondary outcomes

  1. Total Immunoglobulin G (IgG) Geometric Mean Ratios (GMRs) for anti-HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58

    GMR of titers for participants vaccinated with V540D versus those who received GARDASIL®9 alone will be calculated.

    Time frame: Up to approximately 7 months

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2024 (actual). Primary completion is estimated for Jan 2027, 25 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Nov 2026 → Jan 2027 and completion Nov 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2024
First posted
Nov 14, 2024
StartActual
Dec 20, 2024
Primary completionEst.
Jan 29, 2027was Nov 2026
CompletionEst.
Jan 29, 2027was Nov 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 30, 2026→Jan 29, 2027
Nov 12, 2026
Study completion
Nov 30, 2026→Jan 29, 2027
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Nov 30, 2026→Jan 29, 2027
    Study completion Nov 30, 2026→Jan 29, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06688058
Responsible party
Sponsor
First posted
Nov 14, 2024
Start date
Dec 20, 2024
Primary completion
Jan 29, 2027 (estimated)
Completion
Jan 29, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion